SCHEMBL540776

SCHEMBL540776

CCCCCCC(CC)=C(C#N)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 7/20 0.45
PPARG P37231 7/20 0.45
PPARD Q03181 7/20 0.45
PPARA Q07869 7/20 0.45
HDAC11 Q96DB2 5/20 0.45
TSHR P16473 4/20 0.45
PTPN1 P18031 3/20 0.45
ALDH1A1 P00352 2/20 0.45
TLR2 O60603 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
FABP4 P15090 2/20 0.45
SLC22A6 Q4U2R8 1/20 0.45
SLC22A8 Q8TCC7 1/20 0.45
MEN1 O00255 1/20 0.45
ESR1 P03372 1/20 0.45
ALOX15 P16050 1/20 0.45
PDE4A P27815 1/20 0.45
KMT2A Q03164 1/20 0.45
PDE3A Q14432 1/20 0.45
HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8673175 0.98 AKR1B1 (0.43) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL8673179 0.98 AKR1B1 (0.43) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL7545293 0.93 CES1 (0.39) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL11910004 0.93 KMT2A (0.48) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL31625063 0.93 KMT2A (0.48) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL7548078 0.91 KMT2A (0.47) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL7542466 0.91 KMT2A (0.47) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL1074448 0.91 AKR1B1 (0.46) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL7542632 0.89 AKR1B1 (0.45) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL7546476 0.85 CES1 (0.41) GPR84PPARGPPARDPPARAHDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230138395-A1 PHARMACEUTICAL COMPOSITIONS OF A THERAPEUTIC POLYENE MACROLIDE AND METHODS OF THEIR USE BIOSERGEN AS (NO) 2023-05-04 US claimed
EP-4110305-A1 PHARMACEUTICAL COMPOSITIONS OF A THERAPEUTIC POLYENE MACROLIDE AND METHODS OF THEIR USE Biosergen AS (NO) 2023-01-04 EP claimed
US-20230138395-A1 PHARMACEUTICAL COMPOSITIONS OF A THERAPEUTIC POLYENE MACROLIDE AND METHODS OF THEIR USE BIOSERGEN AS (NO) 2023-05-04 US disclosed
EP-4110305-A1 PHARMACEUTICAL COMPOSITIONS OF A THERAPEUTIC POLYENE MACROLIDE AND METHODS OF THEIR USE Biosergen AS (NO) 2023-01-04 EP disclosed
US-8618003-B2 Method of making electronic devices using selective deposition EASTMAN KODAK COMPANY (US) 2013-12-31 US disclosed
WO-2013085941-A1 SELECTIVE DEPOSITION BY USE OF A POLYMERIC MASK EASTMAN KODAK COMPANY (US) 2013-06-13 WO disclosed
US-20130140064-A1 METHOD OF MAKING ELECTRONIC DEVICES USING SELECTIVE DEPOSITION BANK OF AMERICA, N.A., AS AGENT 2013-06-06 US disclosed
US-8199176-B2 Laser thermal donor elements and method of use EASTMAN KODAK COMPANY (US) 2012-06-12 US disclosed
EP-1647262-B2 Anhydrous cosmetic composition comprising electrophilic monomers and acid, and use for cosmetic treatment of hair OREAL (FR) 2012-02-08 EP disclosed
WO-2011149813-A1 LASER THERMAL DONOR ELEMENTS AND METHOD OF USE EASTMAN KODAK COMPANY (US) 2011-12-01 WO disclosed
EP-1647262-B1 Anhydrous cosmetic composition comprising electrophilic monomers and acid, and use for cosmetic treatment of hair OREAL (FR) 2009-08-05 EP disclosed
EP-1647264-A1 use for cosmetic treatment of keratinic material of a composition comprising an electrophilic monomer and a non-siloxane polymer, thereby achieving a rigid coating L'OREAL (FR) 2006-04-19 EP disclosed
EP-1647259-A1 use for treatment of keratinic materials of compositions comprising electrophilic monomers and agents forming liquid crystals L'OREAL (FR) 2006-04-19 EP disclosed
US-20060073426-A1 Method for simulating spot varnish on a surprint proof EASTMAN KODAK COMPANY 2006-04-06 US disclosed
EP-1112859-B1 Donor element for laser-induced thermal transfer EASTMAN KODAK CO (US) 2004-05-19 EP disclosed
EP-1151872-A2 Donor element for laser-induced image transfer EASTMAN KODAK COMPANY (US) 2001-11-07 EP disclosed
EP-1112859-A2 Donor element for laser-induced thermal transfer EASTMAN KODAK COMPANY (US) 2001-07-04 EP disclosed
US-6190827-B1 A LASER-INDUCED WHITE TRANSFER IMAGE. EASTMAN KODAK COMPANY 2001-02-20 US disclosed
US-6165671-A Laser donor element EASTMAN KODAK COMPANY (US) 2000-12-26 US disclosed
US-5576144-A SUPPORT WITH COLOR LAYER DISPERSED IN POLYMER BINDER EASTMAN KODAK COMPANY (US) 1996-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230138395-A1 PHARMACEUTICAL COMPOSITIONS OF A THERAPEUTIC POLYENE MACROLIDE AND METHODS OF THEIR USE CEL, LIPA, HDAC6 GPR84 4180/4885PPARG 1627/4885PPARD 2640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.